NEULANDLAB
Neuland Laboratories Limited (NEULANDLAB) Stock Analysis
Neuland Laboratories Limited is an Indian pharmaceutical company focused on APIs and complex chemistry for regulated markets with manufacturing sites in Telangana. It serves innovators and generics with niche molecules. Export mix and capacity utilization drive growth. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹20,890.00
-2.86% 1W | +28.80% 52W
Market Cap
26.8k CR
P/E Ratio
53.8
52W High
₹24225
52W Low
₹11500
Div. Yield
0.16%
Beta
0.3
50 DMA
₹22422.2
200 DMA
₹17088.5
Profit Margin
21%
Inst. Own.
28.1%
🔥 APPROACHING RESISTANCE
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Expenses | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 |
| Operating Profit | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 |
| OPM % | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% |
| Other Income | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 |
| Interest | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before tax | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 |
| Tax % | 26% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net Profit | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 |
| EPS in Rs | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.68 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 | 2,372 |
| Expenses | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,096 | 1,146 | 1,443 | 1,609 |
| Operating Profit | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 580 | 763 |
| OPM % | 14% | 16% | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% | 22% | 29% | 32% |
| Other Income | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 90 | 25 | 31 |
| Interest | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 14 | 8 | 24 | 26 |
| Depreciation | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 92 | 98 |
| Profit before tax | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 489 | 669 |
| Tax % | 36% | 36% | 30% | 13% | 19% | 69% | 23% | 22% | 24% | 25% | 25% | 26% | |
| Net Profit | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 364 | 498 |
| EPS in Rs | 17.96 | 30.75 | 52.74 | 13.57 | 12.81 | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 | 387.97 |
| Dividend Payout % | 8% | 7% | 0% | 0% | 0% | 16% | 8% | 10% | 8% | 6% | 6% | 12% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 19.0% | 17.0% | 15.0% |
| Profit CAGR | 30.0% | 39.0% | 29.0% |
Shareholding Pattern
Promoters32.67%
FIIs21.69%
DIIs11.57%
Public33.67%
Promoters32.64%
FIIs20.60%
DIIs13.55%
Public32.80%
Promoters32.63%
FIIs20.90%
DIIs14.72%
Public31.76%
Promoters32.63%
FIIs20.46%
DIIs15.84%
Public31.08%
Promoters32.62%
FIIs21.08%
DIIs16.52%
Public29.79%
Promoters36.14%
FIIs18.14%
DIIs7.10%
Public38.22%
Promoters32.74%
FIIs24.43%
DIIs6.54%
Public35.88%
Promoters32.67%
FIIs22.12%
DIIs10.97%
Public33.85%
Promoters32.63%
FIIs20.46%
DIIs15.84%
Public31.08%
Promoters32.62%
FIIs21.08%
DIIs16.52%
Public29.79%
NEULANDLAB
Holdings Analysis
Key strengths & risk signals
73
Overall
75
Fundamental
72
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.16% yield - little to no income.
RECOVERY MODE! Current price (20890.0) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -2.9% (1 week), -9.9% (1 month), 7.1% (3 months).
Strengths (4)
EXCELLENT EFFICIENCY! 21.0% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (22422.2) is above 200-day average (17088.5) - positive signal.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 53,033 vs down days: 42,446. Ratio: 1.25x
Fundamental & Technical Analysis
73Overall
75Fundamental
72Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 18.5% (VERY GOOD, 13/15). Profit CAGR: 30.6% (EXCELLENT, 15/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 21.0% profit margin - company keeps strong profits.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.76 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.16% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 36.62% public ownership - moderate retail influence.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (22422.2) is above 200-day average (17088.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (20890.0) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
8/10
GOOD YEAR! Stock gained 28.8% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 53,033 vs down days: 42,446. Ratio: 1.25x
RSI
4/5
APPROACHING OVERSOLD! RSI at 36.3 - watch for reversal.
52W Range
4/5
UPPER HALF! Trading at 73.8% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -2.9% (1 week), -9.9% (1 month), 7.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
NEULANDLAB
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-10 | Concall PDF | |
| Q4FY262026-05-16 | Concall PDF | |
| Q3FY262026-02-13 | Concall PDF | |
| Q2FY262025-11-12 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEULANDLAB | ₹20,890.00 | 53.8 | 21.0% | 18.5% | 30.6% | +28.8% | 73 | BREAKDOWN | +962.6% | -30.6% | +119.1% | -17.4% |
| PPLPHARMA | ₹196.90 | – | -3.4% | 7.6% | – | -2.6% | 57 | BOUNCE FROM SUPPORT | -15.1% | +688.6% | +17.4% | -17.5% |
| GRANULES | ₹815.20 | 30.3 | 11.8% | 5.9% | 4.8% | +48.7% | 64 | CONSOLIDATION | +59.9% | -10.7% | +21.2% | +0.5% |
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
Data from TradeAlone · Updated daily
NEULANDLAB News
Neuland Laboratories Limited (NEULANDLAB) clears resistance, moves up 6%2026-08-07Neuland Laboratories Limited (NEULANDLAB) clears resistance, gains 10% intraday2026-08-06Neuland Laboratories Limited (NEULANDLAB) clears resistance, gains 6% intraday2026-08-06Neuland Laboratories Limited (neulandlab) Q1fy27: Total Income Rs. 650.1 Crore; Ebitda Rs. 231.1 Crore2026-08-05Neuland Laboratories Limited (NEULANDLAB) breaks out, gains 5% intraday2026-07-09Neuland Laboratories Limited (NEULANDLAB) gains 5% intraday, nears resistance2026-06-23Neuland Q4fy26 Total Income Up 134.9% to Rs. 2053.1 Crore2026-05-12
